Novaliq GmbH, based in Heidelberg, is a drug delivery company that is developing a superior generation of innovative ocular formulations for poorly soluble drugs.
Novaliq's technology platform is based and built on highly purified semifluorinated alkanes (SFAs).
Its patented SFAs can be used in various routes of administration for the transport of drugs or oxygen for therapeutic purposes. Based on their unique physicochemical properties, they have a high oxygen dissolution capacity and excellent spreading properties on aqueous surfaces.
These biocompatible liquids can be easily applied in the form of topical eye drops. Their amphiphilic profile makes SFAs ideal for the production of purely physically active drug solutions or homogenous suspensions for ocular applications.
Novaliq has several product candidates with excellent market potential in various stages of preclinical and clinical development. These include ophthalmic, dermal and organ preservation products.
Their first and preservative free eye drop product (OTC) is NovaTears™ for the relief of discomfort under dry eye syndrome.